Results 61 to 70 of about 14,917 (287)

Edaravone alleviates lung damage in mice with hypoxic pulmonary hypertension by increasing nitric oxide synthase 3 expression

open access: yesKorean Journal of Physiology and Pharmacology, 2023
This study is to determine the regulation of nitric oxide synthase 3 (NOS3) by edaravone in mice with hypoxic pulmonary hypertension (HPH). C57BL/6J mice were reared in a hypoxic chamber.
Wan Zheng   +4 more
semanticscholar   +1 more source

Role of edaravone in managemant of septic peritonitis

open access: yesJournal of Anaesthesiology Clinical Pharmacology, 2016
Sepsis is a complex rapidly progressive infectious disease that remain a major cause of morbidity and mortality in surgical patients and trauma victims. Edaravone a novel free radical scavenger was approved in 2001 in Japan for treatment of acute cerebral and myocardial infarction.
Nagat S. Elshmaa   +2 more
openaire   +4 more sources

The Therapeutic Efficacy of Edaravone in Extensively Burned Rats [PDF]

open access: yesArchives of Surgery, 2006
Extensive burn injury leads to production of free radicals subsequent to massive fluid resuscitation, which in turn increases the risk of acute lung injury. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, is clinically effective in improving the prognosis after cerebral infarction.
Seiki Sakaki   +3 more
openaire   +3 more sources

Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress [PDF]

open access: yes, 2017
Accumulating evidence shows that oxidative stress is involved in a wide variety of human diseases: rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, cancers, etc.
Ahmadinejad, Fereshteh.   +4 more
core   +2 more sources

Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke

open access: yesJAMA Neurology
This randomized clinical trial investigates if sublingual edaravone dexborneol improves functional outcome in patients with acute ischemic stroke.
Yu Fu   +27 more
semanticscholar   +1 more source

New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments

open access: yesMolecules, 2023
Currently, there are no effective drugs for the treatment of amyotrophic lateral sclerosis (ALS). Only two drugs—edaravone and riluzole—have been approved, but they have very limited efficacy. The aim of this work was to modify the structural core of the
M. A. Lapshina   +15 more
semanticscholar   +1 more source

Edaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cells [PDF]

open access: yes, 2014
BACKGROUND: Elevated level of reactive carbonyl species, such as methylglyoxal, triggers carbonyl stress and activates a series of inflammatory responses leading to accelerated vascular damage. Edaravone is the active substance of a Japanese medicine,
Bocsik, Alexandra   +11 more
core   +6 more sources

Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases

open access: yesInternational Journal of Molecular Sciences
The brain is susceptible to oxidative stress, which is associated with various neurological diseases. Edaravone (MCI-186, 3-methyl-1 pheny-2-pyrazolin-5-one), a free radical scavenger, has promising effects by quenching hydroxyl radicals (∙OH) and ...
Toru Yamashita, Koji Abe
semanticscholar   +1 more source

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis

open access: yesMuscle and Nerve, 2023
Intravenous (IV) edaravone is a US Food and Drug Administration–approved treatment for amyotrophic lateral sclerosis (ALS), shown in clinical trials to slow physical functional decline.
B. R. Brooks   +5 more
semanticscholar   +1 more source

Edaravone prevents high glucose-induced injury in retinal Müller cells through thioredoxin1 and the PGC-1α/NRF1/TFAM pathway

open access: yesPharmaceutical Biology, 2021
Context Oxidative injury in a high-glucose (HG) environment may be a mechanism of diabetic retinopathy (DR) and edaravone can protect retinal ganglion cells by scavenging ROS. Objective To explore the effect of edaravone on HG-induced injury.
Juanping Yin, Xinke Chen
doaj   +1 more source

Home - About - Disclaimer - Privacy